Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).


Clinical Trial Description

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the links provided in More Information. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02939820
Study type Expanded Access
Source Alnylam Pharmaceuticals
Contact
Status Approved for marketing
Phase

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05974644 - Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
Recruiting NCT05879874 - Prospective Evaluation of NfL as a Biomarker in ATTRv
Recruiting NCT05489549 - Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Completed NCT01960348 - APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Phase 3
Active, not recruiting NCT03759379 - HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) Phase 3
Completed NCT02319005 - ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) Phase 3
Recruiting NCT05873868 - Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
Approved for marketing NCT03400098 - ATTR Expanded Access Program (EAP) by Ionis